Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses

Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses
When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with recurrent ovarian cancer — particularly those whose tumors contain high levels of the protein folate receptor alpha (FRα), top-line data from a Phase 1b/2 trial shows. The trial findings were presented in “Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer,” an oral presentation given recently at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) currently being developed by ImmunoGen for the treatment of ovarian cancer and other types of solid tumors. It is made up of an antibody that specifically binds to FRα, a protein found in high levels in most types of ovarian cancer. When the antibody binds to its target, it releases a toxic compound, called maytansinoid DM4, that kills cancer cel
Subscribe or to access all post and page content.